RIPK1 inhibition limits expansion of pathogenic double-negative T cells in preclinical autoimmune lymphoproliferative syndrome models
Autoimmune lymphoproliferative syndrome (ALPS) is an immune disorder characterized by defective lymphocyte apoptosis, leading to lymphoproliferation, autoimmunity, and increased lymphoma risk. Although disease severity correlates with the expansion of double-negative T (DNT) cells, the mechanisms governing their aberrant generation and pathogenicity remain elusive. Through single-cell transcriptomics of peripheral blood from pediatric patients with ALPS, including patients harboring new FAS cell surface death receptor (FAS) mutations ( FAS mutations), we identified a pathogenic effector DNT subset (GRANZYME hi CXCR5 hi ) exhibiting cytotoxic and tissue-infiltrating features, a population conserved in ALPS mouse models. Using an apoptosis-defective murine model that develops early-onset ALPS with robust DNT cell expansion, we found that ALPS-associated caspase-8 functional impairment facilitates receptor-interacting serine/threonine-protein kinase 1 (RIPK1) activation to drive disease pathogenesis, a process exacerbated by receptor-interacting serine/threonine-protein kinase 3 (RIPK3) scaffold function. Peripheral CD8 + T cells from both patients with ALPS and mouse models exhibited increased susceptibility to activation-induced conversion into pathogenic DNT cells, which was effectively blocked by RIPK1 inhibition. Mechanistically, RIPK1 activation drove peripheral CD8 + T cells to adopt a pathogenic DNT fate via cAMP-responsive element modulator (CREM)–mediated CD8 silencing. Furthermore, genetic or pharmacological inhibition of RIPK1 kinase activity reduced DNT cell generation and burden in target organs, reversed cytopenias, and alleviated autoimmune pathology in ALPS mouse models. Our findings establish RIPK1 as a critical driver of ALPS pathogenesis and identify RIPK1 inhibition as a promising therapeutic strategy.
Authors
- Hu Liu (ORCID: https://orcid.org/0000-0002-3952-4165)
- Xiaoliang Yu (ORCID: https://orcid.org/0000-0002-1117-7157)
- Haikuo Ma
- Xiangping Xu
- Sudan He (ORCID: https://orcid.org/0000-0002-0846-1210)
- Qiuye Li
- Shaoyan Hu (ORCID: https://orcid.org/0000-0002-3386-6957)
- Jingjing Li (ORCID: https://orcid.org/0000-0002-0047-3217)
- Junjie Fan (ORCID: https://orcid.org/0009-0004-5697-0628)
- Yayun Du (ORCID: https://orcid.org/0000-0002-3483-6522)
- Wei Zhang (ORCID: https://orcid.org/0000-0002-5057-7794)
- Xiaohu Zhang (ORCID: https://orcid.org/0000-0002-0579-1636)
- Zhizhuo Du
- Cong Zhao
- Dongmei Cao
- Jiaying Qiu (ORCID: https://orcid.org/0009-0008-5005-0133)
- Zhanhui Li
- Rui Li
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Soochow University (CN)
- Suzhou Institute of Systems Medicine (CN)
- Children's Hospital of Suzhou University (CN)
Publication Details
- Journal
- Science Translational Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1126/scitranslmed.aeb1037
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Chinese Academy of Medical Sciences
- Peking Union Medical College
- Directorate for Biological Sciences
- Basic Research Program of Jiangsu Province
- National Key Research and Development Program of China